Evidence map›Paper›PMID 27622077›Full record

ArticleOncoimmunology2016

Targeting CD73 in the tumor microenvironment with MEDI9447.

Carl M Hay, Erin Sult, Qihui Huang, Kathy Mulgrew, Stacy R Fuhrmann, Kelly A McGlinchey, Scott A Hammond, Raymond Rothstein, Jonathan Rios-Doria, Edmund Poon and 8 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02503774 (A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors), which is not on this map. Cited by 187 papers.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02503774 phase1completednot on this map

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

TypeinterventionalSponsorMedImmune LLCRan2015 to 2023Enrolled192ConditionsSolid TumorsArmsOleclumab, Durvalumab
3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 283 citations in OpenAlex.

  1. Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. The next generation of immunotherapies for lung cancers.Nature reviews. Clinical oncology · 2025
    Review
  18. Review
  19. Review
  20. Insights from Clinical Trials on AACS pharmacology & translational science · 2025
    Review

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Carl M HayMedImmune, LLC , Gaithersburg, MD, USA.
Erin SultMedImmune, LLC , Gaithersburg, MD, USA.
Qihui HuangMedImmune, LLC , Gaithersburg, MD, USA.
Kathy MulgrewMedImmune, LLC , Gaithersburg, MD, USA.
Stacy R FuhrmannMedImmune, LLC , Gaithersburg, MD, USA.
Kelly A McGlincheyMedImmune, LLC , Gaithersburg, MD, USA.
Scott A HammondMedImmune, LLC , Gaithersburg, MD, USA.
Raymond RothsteinMedImmune, LLC , Gaithersburg, MD, USA.
Jonathan Rios-DoriaMedImmune, LLC , Gaithersburg, MD, USA.
Edmund PoonMedimmune, LLC, MedImmune , Cambridge, UK.
Nick HoloweckyjMedImmune, LLC , Gaithersburg, MD, USA.
Nicholas M DurhamMedImmune, LLC , Gaithersburg, MD, USA.
Ching Ching LeowAstrazeneca , Gaithersburg, MD, USA.
Gundo DiedrichMacrogenics, MacroGenics, Inc. , Rockville, MD, USA.
Melissa DamschroderMedImmune, LLC , Gaithersburg, MD, USA.
Ronald HerbstMedImmune, LLC , Gaithersburg, MD, USA.
Robert E HollingsworthMedImmune, LLC , Gaithersburg, MD, USA.
Kris F SachsenmeierMedImmune, LLC , Gaithersburg, MD, USA.
MacroGenics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences. MEDI9447 results in relief from adenosine monophosphate (AMP)-mediated lymphocyte suppression in vitro and inhibition of mouse syngeneic tumor growth in vivo. In contrast with other cancer immunotherapy agents such as checkpoint inhibitors or T-cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment of mouse models. Changes include significant alterations in a number of tumor micro-environmental subpopulations including increases in CD8(+) effector cells and activated macrophages. Furthermore, these changes correlate directly with responder and non-responder subpopulations within animal studies using syngeneic tumors. Combination data showing additive activity between MEDI9447 and anti-PD-1 antibodies using human cells in vitro and mouse tumor models further demonstrate the potential value of relieving adenosine-mediated immunosuppression. Based on these data, a Phase I study to test the safety, tolerability, and clinical activity of MEDI9447 in cancer patients was initiated (NCT02503774).

Indexed as

AdenosineCD73MEDI9447monoclonal antibodysyngeneic tumor modeltumor microenvironment

Identifiers

PMID27622077
PMCPMC5007986
OpenAlexW2474535137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.